Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 196 entries
Sorted by: Best Match Show Resources per page
Effect of oral azithromycin vs placebo on COVID-19 symptoms in outpatients with SARS-CoV-2 infection: a randomized clinical trial

Latinx/Hispanic ethnicity

Oldenburg CE, Pinsky BA, Ruder K.
GSID: gkpLBSD1X4QJ
CE Oldenburg, BA Pinsky, J Brogdon, C Chen, K Ruder… - Jama, 2021 - jamanetwork.com

… Race and ethnicity were self-reported by participants based on fixed categories with the option to report an “other” race or ethnicity to comply with US Food and Drug Administration …

Cite
Oldenburg, C. E., Pinsky, B. A., Brogdon, J., Chen, C., Ruder, K., Zhong, L., ... & Doan, T. (2021). Effect of oral azithromycin vs placebo on COVID-19 symptoms in outpatients with SARS-CoV-2 infection: a randomized clinical trial. Jama, 326(6), 490-498.
Oldenburg, Catherine E., et al. "Effect of oral azithromycin vs placebo on COVID-19 symptoms in outpatients with SARS-CoV-2 infection: a randomized clinical trial." Jama 326.6 (2021): 490-498.
Copy Download .nbib Format: MLA
Improved glycerol utilization by a triacylglycerol-producing Rhodococcus opacus strain for renewable fuels.

Biotechnology for biofuels

Kurosawa K, Radek A, Plassmeier JK, Sinskey AJ.
PMID: 25763105
Biotechnol Biofuels. 2015 Feb 26;8:31. doi: 10.1186/s13068-015-0209-z. eCollection 2015.

BACKGROUND: Glycerol generated during renewable fuel production processes is potentially an attractive substrate for the production of value-added materials by fermentation. An engineered strain MITXM-61 of the oleaginous bacterium Rhodococcus opacus produces large amounts of intracellular triacylglycerols (TAGs) for...

Cite
Kurosawa K, Radek A, Plassmeier JK, et al. Improved glycerol utilization by a triacylglycerol-producing Rhodococcus opacus strain for renewable fuels. Biotechnol Biofuels. 2015;8:31doi: 10.1186/s13068-015-0209-z.
Kurosawa, K., Radek, A., Plassmeier, J. K., & Sinskey, A. J. (2015). Improved glycerol utilization by a triacylglycerol-producing Rhodococcus opacus strain for renewable fuels. Biotechnology for biofuels, 831. https://doi.org/10.1186/s13068-015-0209-z
Kurosawa, Kazuhiko, et al. "Improved glycerol utilization by a triacylglycerol-producing Rhodococcus opacus strain for renewable fuels." Biotechnology for biofuels vol. 8 (2015): 31. doi: https://doi.org/10.1186/s13068-015-0209-z
Kurosawa K, Radek A, Plassmeier JK, Sinskey AJ. Improved glycerol utilization by a triacylglycerol-producing Rhodococcus opacus strain for renewable fuels. Biotechnol Biofuels. 2015 Feb 26;8:31. doi: 10.1186/s13068-015-0209-z. eCollection 2015. PMID: 25763105; PMCID: PMC4355421.
Copy Download .nbib Format: NLM
Cell engineering and molecular pharming for biopharmaceuticals.

The open medicinal chemistry journal

Abdullah MA, Rahmah AU, Sinskey AJ, Rha CK.
PMID: 19662143
Open Med Chem J. 2008 May 14;2:49-61. doi: 10.2174/1874104500802010049.

Biopharmaceuticals are often produced by recombinant E. coli or mammalian cell lines. This is usually achieved by the introduction of a gene or cDNA coding for the protein of interest into a well-characterized strain of producer cells. Naturally, each...

Cite
Abdullah MA, Rahmah AU, Sinskey AJ, et al. Cell engineering and molecular pharming for biopharmaceuticals. Open Med Chem J. 2008;2:49-61doi: 10.2174/1874104500802010049.
Abdullah, M. A., Rahmah, A. U., Sinskey, A. J., & Rha, C. K. (2008). Cell engineering and molecular pharming for biopharmaceuticals. The open medicinal chemistry journal, 249-61. https://doi.org/10.2174/1874104500802010049
Abdullah, M A, et al. "Cell engineering and molecular pharming for biopharmaceuticals." The open medicinal chemistry journal vol. 2 (2008): 49-61. doi: https://doi.org/10.2174/1874104500802010049
Abdullah MA, Rahmah AU, Sinskey AJ, Rha CK. Cell engineering and molecular pharming for biopharmaceuticals. Open Med Chem J. 2008 May 14;2:49-61. doi: 10.2174/1874104500802010049. PMID: 19662143; PMCID: PMC2709479.
Copy Download .nbib Format: NLM
Evaluation of hemodynamic parameters as predictors of glaucoma progression.

Journal of ophthalmology

Janulevičiene I, Ehrlich R, Siesky B, Nedzelskienė I, Harris A.
PMID: 21577269
J Ophthalmol. 2011;2011:164320. doi: 10.1155/2011/164320. Epub 2011 Apr 10.

Purpose. To evaluate hemodynamic parameters as possible predictors for glaucoma progression. Methods. An 18-month randomized double-masked cohort study including 30 open-angle glaucoma patients receiving fixed-combination treatment with Dorzolamide/Timolol (DTFC) or Latanoprost/Timolol (LTFC) (n = 15 per group) was performed....

Cite
Janulevičiene I, Ehrlich R, Siesky B, et al. Evaluation of hemodynamic parameters as predictors of glaucoma progression. J Ophthalmol. 2011;2011:164320doi: 10.1155/2011/164320.
Janulevičiene, I., Ehrlich, R., Siesky, B., Nedzelskienė, I., & Harris, A. (2011). Evaluation of hemodynamic parameters as predictors of glaucoma progression. Journal of ophthalmology, 2011164320. https://doi.org/10.1155/2011/164320
Janulevičiene, Ingrida, et al. "Evaluation of hemodynamic parameters as predictors of glaucoma progression." Journal of ophthalmology vol. 2011 (2011): 164320. doi: https://doi.org/10.1155/2011/164320
Janulevičiene I, Ehrlich R, Siesky B, Nedzelskienė I, Harris A. Evaluation of hemodynamic parameters as predictors of glaucoma progression. J Ophthalmol. 2011;2011:164320. doi: 10.1155/2011/164320. Epub 2011 Apr 10. PMID: 21577269; PMCID: PMC3090719.
Copy Download .nbib Format: NLM
Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients.

Clinical ophthalmology (Auckland, N.Z.)

Moss AM, Harris A, Siesky B, Rusia D, Williamson KM, Shoshani Y.
PMID: 20463789
Clin Ophthalmol. 2010 Apr 26;4:233-41. doi: 10.2147/opth.s6372.

Topical hypotensive therapy with both timolol and carbonic anhydrase inhibitors has been shown to be efficacious at reducing intraocular pressure. Many prospective studies have also suggested that carbonic anhydrase inhibitors augment ocular blood flow and vascular regulation independent of...

Cite
Moss AM, Harris A, Siesky B, et al. Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients. Clin Ophthalmol. 2010;4:233-41doi: 10.2147/opth.s6372.
Moss, A. M., Harris, A., Siesky, B., Rusia, D., Williamson, K. M., & Shoshani, Y. (2010). Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients. Clinical ophthalmology (Auckland, N.Z.), 4233-41. https://doi.org/10.2147/opth.s6372
Moss, Adam M, et al. "Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients." Clinical ophthalmology (Auckland, N.Z.) vol. 4 (2010): 233-41. doi: https://doi.org/10.2147/opth.s6372
Moss AM, Harris A, Siesky B, Rusia D, Williamson KM, Shoshani Y. Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients. Clin Ophthalmol. 2010 Apr 26;4:233-41. doi: 10.2147/opth.s6372. PMID: 20463789; PMCID: PMC2861928.
Copy Download .nbib Format: NLM
A streamlined approach to prescription management.

Family practice management

Sinsky TA, Sinsky CA.
PMID: 23317126
Fam Pract Manag. 2012 Nov-Dec;19(6):11-3.

No abstract available.

Cite
Sinsky TA, Sinsky CA. A streamlined approach to prescription management. Fam Pract Manag. 2012;19(6):11-3
Sinsky, T. A., & Sinsky, C. A. (2012). A streamlined approach to prescription management. Family practice management, 19(6), 11-3.
Sinsky, Thomas A, and Sinsky, Christine A. "A streamlined approach to prescription management." Family practice management vol. 19,6 (2012): 11-3.
Sinsky TA, Sinsky CA. A streamlined approach to prescription management. Fam Pract Manag. 2012 Nov-Dec;19(6):11-3. PMID: 23317126.
Copy Download .nbib Format: NLM
Comparison of intraocular pressure, blood pressure, ocular perfusion pressure and blood flow fluctuations during dorzolamide versus timolol add-on therapy in prostaglandin analogue treated glaucoma subjects.

Pharmaceuticals (Basel, Switzerland)

Januleviciene I, Siaudvytyte L, Diliene V, Barsauskaite R, Paulaviciute-Baikstiene D, Siesky B, Harris A.
PMID: 24281382
Pharmaceuticals (Basel). 2012 Mar 21;5(3):325-38. doi: 10.3390/ph5030325.

OBJECTIVE: To compare the effects of dorzolamide and timolol add-on therapy in open-angle glaucoma (OAG) patients previously treated with prostaglandin analogue (Pg), by evaluating fluctuations in the intraocular (IOP), blood (BP), ocular perfusion pressures (OPP) and retrobulbar blood flow...

Cite
Januleviciene I, Siaudvytyte L, Diliene V, et al. Comparison of intraocular pressure, blood pressure, ocular perfusion pressure and blood flow fluctuations during dorzolamide versus timolol add-on therapy in prostaglandin analogue treated glaucoma subjects. Pharmaceuticals (Basel). 2012;5(3):325-38doi: 10.3390/ph5030325.
Januleviciene, I., Siaudvytyte, L., Diliene, V., Barsauskaite, R., Paulaviciute-Baikstiene, D., Siesky, B., & Harris, A. (2012). Comparison of intraocular pressure, blood pressure, ocular perfusion pressure and blood flow fluctuations during dorzolamide versus timolol add-on therapy in prostaglandin analogue treated glaucoma subjects. Pharmaceuticals (Basel, Switzerland), 5(3), 325-38. https://doi.org/10.3390/ph5030325
Januleviciene, Ingrida, et al. "Comparison of intraocular pressure, blood pressure, ocular perfusion pressure and blood flow fluctuations during dorzolamide versus timolol add-on therapy in prostaglandin analogue treated glaucoma subjects." Pharmaceuticals (Basel, Switzerland) vol. 5,3 (2012): 325-38. doi: https://doi.org/10.3390/ph5030325
Januleviciene I, Siaudvytyte L, Diliene V, Barsauskaite R, Paulaviciute-Baikstiene D, Siesky B, Harris A. Comparison of intraocular pressure, blood pressure, ocular perfusion pressure and blood flow fluctuations during dorzolamide versus timolol add-on therapy in prostaglandin analogue treated glaucoma subjects. Pharmaceuticals (Basel). 2012 Mar 21;5(3):325-38. doi: 10.3390/ph5030325. PMID: 24281382; PMCID: PMC3763637.
Copy Download .nbib Format: NLM
Engineering xylose metabolism in triacylglycerol-producing Rhodococcus opacus for lignocellulosic fuel production.

Biotechnology for biofuels

Kurosawa K, Wewetzer SJ, Sinskey AJ.
PMID: 24041310
Biotechnol Biofuels. 2013 Sep 16;6(1):134. doi: 10.1186/1754-6834-6-134.

BACKGROUND: There has been a great deal of interest in fuel productions from lignocellulosic biomass to minimize the conflict between food and fuel use. The bioconversion of xylose, which is the second most abundant sugar present after glucose in...

Cite
Kurosawa K, Wewetzer SJ, Sinskey AJ. Engineering xylose metabolism in triacylglycerol-producing Rhodococcus opacus for lignocellulosic fuel production. Biotechnol Biofuels. 2013;6(1):134doi: 10.1186/1754-6834-6-134.
Kurosawa, K., Wewetzer, S. J., & Sinskey, A. J. (2013). Engineering xylose metabolism in triacylglycerol-producing Rhodococcus opacus for lignocellulosic fuel production. Biotechnology for biofuels, 6(1), 134. https://doi.org/10.1186/1754-6834-6-134
Kurosawa, Kazuhiko, et al. "Engineering xylose metabolism in triacylglycerol-producing Rhodococcus opacus for lignocellulosic fuel production." Biotechnology for biofuels vol. 6,1 (2013): 134. doi: https://doi.org/10.1186/1754-6834-6-134
Kurosawa K, Wewetzer SJ, Sinskey AJ. Engineering xylose metabolism in triacylglycerol-producing Rhodococcus opacus for lignocellulosic fuel production. Biotechnol Biofuels. 2013 Sep 16;6(1):134. doi: 10.1186/1754-6834-6-134. PMID: 24041310; PMCID: PMC3848844.
Copy Download .nbib Format: NLM
Simultaneous wavelength locking of microring modulator array with a single monitoring signal.

Optics express

Dong P, Gatdula R, Kim K, Sinsky JH, Melikyan A, Chen YK, de Valicourt G, Lee J.
PMID: 28789112
Opt Express. 2017 Jul 10;25(14):16040-16046. doi: 10.1364/OE.25.016040.

A microring modulator array coupled to a common bus waveguide can be used to construct low power, compact and flexible wavelength-division-multiplexing (WDM) transmitters. However, due to extremely small working bandwidths of the rings, it is challenging to find the...

Cite
Dong P, Gatdula R, Kim K, et al. Simultaneous wavelength locking of microring modulator array with a single monitoring signal. Opt Express. 2017;25(14):16040-16046doi: 10.1364/OE.25.016040.
Dong, P., Gatdula, R., Kim, K., Sinsky, J. H., Melikyan, A., Chen, Y. K., de Valicourt, G., & Lee, J. (2017). Simultaneous wavelength locking of microring modulator array with a single monitoring signal. Optics express, 25(14), 16040-16046. https://doi.org/10.1364/OE.25.016040
Dong, Po, et al. "Simultaneous wavelength locking of microring modulator array with a single monitoring signal." Optics express vol. 25,14 (2017): 16040-16046. doi: https://doi.org/10.1364/OE.25.016040
Dong P, Gatdula R, Kim K, Sinsky JH, Melikyan A, Chen YK, de Valicourt G, Lee J. Simultaneous wavelength locking of microring modulator array with a single monitoring signal. Opt Express. 2017 Jul 10;25(14):16040-16046. doi: 10.1364/OE.25.016040. PMID: 28789112.
Copy Download .nbib Format: NLM
Corrigendum to "Experimental evolution and gene knockout studies reveal AcrA-mediated isobutanol tolerance in Ralstonia eutropha" [J Biosci Bioeng 122 (2016) 64-69].

Journal of bioscience and bioengineering

Bernardi AC, Gai CS, Lu J, Sinskey AJ, Brigham CJ.
PMID: 28185833
J Biosci Bioeng. 2017 May;123(5):658. doi: 10.1016/j.jbiosc.2017.01.010. Epub 2017 Feb 06.

No abstract available.

Cite
Bernardi AC, Gai CS, Lu J, et al. Corrigendum to "Experimental evolution and gene knockout studies reveal AcrA-mediated isobutanol tolerance in Ralstonia eutropha" [J Biosci Bioeng 122 (2016) 64-69]. J Biosci Bioeng. 2017;123(5):658doi: 10.1016/j.jbiosc.2017.01.010.
Bernardi, A. C., Gai, C. S., Lu, J., Sinskey, A. J., & Brigham, C. J. (2017). Corrigendum to "Experimental evolution and gene knockout studies reveal AcrA-mediated isobutanol tolerance in Ralstonia eutropha" [J Biosci Bioeng 122 (2016) 64-69]. Journal of bioscience and bioengineering, 123(5), 658. https://doi.org/10.1016/j.jbiosc.2017.01.010
Bernardi, Amanda C, et al. "Corrigendum to "Experimental evolution and gene knockout studies reveal AcrA-mediated isobutanol tolerance in Ralstonia eutropha" [J Biosci Bioeng 122 (2016) 64-69]." Journal of bioscience and bioengineering vol. 123,5 (2017): 658. doi: https://doi.org/10.1016/j.jbiosc.2017.01.010
Bernardi AC, Gai CS, Lu J, Sinskey AJ, Brigham CJ. Corrigendum to "Experimental evolution and gene knockout studies reveal AcrA-mediated isobutanol tolerance in Ralstonia eutropha" [J Biosci Bioeng 122 (2016) 64-69]. J Biosci Bioeng. 2017 May;123(5):658. doi: 10.1016/j.jbiosc.2017.01.010. Epub 2017 Feb 06. PMID: 28185833.
Copy Download .nbib Format: NLM
Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2.

Antibody therapeutics

Guttieres D, Sinskey AJ, Springs SL.
PMID: 33928236
Antib Ther. 2021 Mar 20;4(1):60-71. doi: 10.1093/abt/tbab006. eCollection 2021 Jan.

BACKGROUND: Neutralizing antibodies (nAbs) against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) can play an important role in reducing impacts of the COVID-19 pandemic, complementing ongoing public health efforts such as diagnostics and vaccination. Rapidly designing, manufacturing and distributing...

Cite
Guttieres D, Sinskey AJ, Springs SL. Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2. Antib Ther. 2021;4(1):60-71doi: 10.1093/abt/tbab006.
Guttieres, D., Sinskey, A. J., & Springs, S. L. (2021). Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2. Antibody therapeutics, 4(1), 60-71. https://doi.org/10.1093/abt/tbab006
Guttieres, Donovan, et al. "Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2." Antibody therapeutics vol. 4,1 (2021): 60-71. doi: https://doi.org/10.1093/abt/tbab006
Guttieres D, Sinskey AJ, Springs SL. Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2. Antib Ther. 2021 Mar 20;4(1):60-71. doi: 10.1093/abt/tbab006. eCollection 2021 Jan. PMID: 33928236; PMCID: PMC8022923.
Copy Download .nbib Format: NLM
Large-scale cultured meat production: Trends, challenges and promising biomanufacturing technologies.

Biomaterials

Chen L, Guttieres D, Koenigsberg A, Barone PW, Sinskey AJ, Springs SL.
PMID: 34871881
Biomaterials. 2021 Nov 25;280:121274. doi: 10.1016/j.biomaterials.2021.121274. Epub 2021 Nov 25.

Food systems of the future will need to face an increasingly clear reality - that a protein-rich diet is essential for good health, but traditional meat products will not suffice to ensure safety, sustainability, and equity of food supply...

Cite
Chen L, Guttieres D, Koenigsberg A, et al. Large-scale cultured meat production: Trends, challenges and promising biomanufacturing technologies. Biomaterials. 2021;280:121274doi: 10.1016/j.biomaterials.2021.121274.
Chen, L., Guttieres, D., Koenigsberg, A., Barone, P. W., Sinskey, A. J., & Springs, S. L. (2021). Large-scale cultured meat production: Trends, challenges and promising biomanufacturing technologies. Biomaterials, 280121274. https://doi.org/10.1016/j.biomaterials.2021.121274
Chen, Lu, et al. "Large-scale cultured meat production: Trends, challenges and promising biomanufacturing technologies." Biomaterials vol. 280 (2021): 121274. doi: https://doi.org/10.1016/j.biomaterials.2021.121274
Chen L, Guttieres D, Koenigsberg A, Barone PW, Sinskey AJ, Springs SL. Large-scale cultured meat production: Trends, challenges and promising biomanufacturing technologies. Biomaterials. 2021 Nov 25;280:121274. doi: 10.1016/j.biomaterials.2021.121274. Epub 2021 Nov 25. PMID: 34871881.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 196 entries